Shares of Actinium Pharmaceuticals, Inc. (NYSE:ATNM – Get Free Report) have been assigned an average rating of “Moderate Buy” ...

Actinium Pharmaceuticals (NYSE:ATNM) traded higher on Tuesday as H.C. Wainwright highlighted its buyout potential after its ...

In a report released today, Joseph Pantginis from H.C. Wainwright maintained a Buy rating on Actinium Pharmaceuticals (ATNM – Research Report), ...

If you’re in the market for an intriguing biotech pick and can manage high risk, take a look at Actinium Pharmaceuticals (NYSEAMERICAN:ATNM)stock. Actinium Pharmaceuticals develops targeted ...

Actinium Pharma is on course to submit its targeted radiotherapy for acute myeloid leukaemia (AML) patients needing a bone marrow transplant in the US, buoyed by top-line data from a pivotal trial.

Shares in Actinium Pharmaceuticals have lost almost two-thirds of their value after the FDA asked for a second clinical trial before it would consider reviewing the company's Iomab-B radioligand ...

Actinium Pharmaceuticals, Inc. (NYSE:ATNM – Get Free Report) has been assigned a consensus rating of “Moderate Buy” from the five brokerages that are currently covering the stock ...

Find the latest Actinium Pharmaceuticals, Inc. ATNM analyst stock forecast, price target, and recommendation trends with in-depth analysis from research reports.

Actinium Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel targeted therapies. It also develops and markets medicines for relapsed or ...

What Are Magnificent 7 Stocks? The Magnificent Seven has emerged as a replacement for FAANG stocks.

Reveal insider sentiment with alternative data that tracks buy and sell trades made by top managers and company directors.